Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
Zipalertinib demonstrated promising efficacy and a manageable safety profile in heavily pretreated NSCLC patients with EGFR exon 20 insertion mutations who progressed on amivantamab, with an ORR of 40% in the overall population and 50% in the prior amivantamab-only population, according to data from the phase 2b REZILIENT1 trial presented at ESMO Congress 2024.
Related Clinical Trials
Reference News
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
Zipalertinib demonstrated promising efficacy and a manageable safety profile in heavily pretreated NSCLC patients with EGFR exon 20 insertion mutations who progressed on amivantamab, with an ORR of 40% in the overall population and 50% in the prior amivantamab-only population, according to data from the phase 2b REZILIENT1 trial presented at ESMO Congress 2024.